Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of Mosapride Versus Placebo in the Treatment of Constipation-Predominant Irritable Bowel Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Rome III Criteria for IBS:~Patients must have recurrent abdominal pain or discomfort at least 3 days per month during the previous 3 months that is associated with 2 or more of the following:~* Relieved by defecation~* Onset associated with a change in stool frequency~* Onset associated with a change in stool form or appearance~In addition, patients have to experience at least two of the following symptoms for at least 25% of the time \[11\]:~* Altered stool frequency (\< 3 bowel movements per week)~* Altered stool form (lumpy/hard i.e. Bristol type I-III \[see appendix 1\])~* Altered stool passage (straining, urgency, or a feeling of incomplete evacuation)~* Passage of mucus, bloating, or a feeling of abdominal distension~Exclusion Criteria:~* Previous allergy to mosapride~* Nocturnal Symptoms (pain in the middle of the night, or other nocturnal symptoms which suggest an organic disease)~* Age \< 18 years~* History of bloody stools or melena~* Diarrhea (\>3 bowel movements per day)~* Constitutional symptoms (fever, weight loss)~* Severe constipation (\< 1 bm/week)~* Pregnancy or lactation~* Patients with history of cardiac arrhythmias~* QT prolongation on baseline ECG~* Chronic laxative use and dependence~* Patients with previous history of congenital heart disease~* Patients with previous history of hypokalemia or hyperkalemia~* Patients taking the following classes of drugs: HIV antivirals, macrolides, anti-arrhythmics, and azole drugs.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Mosapride
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).